ClinicalTrials.gg
Enrolling by invitationNCT06795126Updated Aug 11, 2026

Little NIRVANA for Pediatric Pain and Anxiety

An interventional study of Little NIRVANA in Acute Pain, Procedural Anxiety and Pediatric ALL, sponsored by Nationwide Children's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 2 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
2 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Planned enrollment
112th of 322
130 · median 86
Started
2025
with 14 others
No phase
122 of 353
24 open now
Primary completion
2026-11
later than 12 of 54 live
Registered
325th of 353
by date
Lead sponsor
6 of 353
Nationwide Children's Hospital

Among the 353 studies in Acute Pain with a site in United States, this one is the 112th largest by planned enrollment of the 322 interventional ones that give a count, is one of 15 that started in 2025, is one of 122 with no phase, reaches primary completion later than 12 of the 54 other live ones, and was the 325th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 2 Years to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to test the feasibility of using Little NIRVANA (augmented reality (AR)) for managing anxiety and pain for children 2-8 years old during hospital emergency peripheral intravenous (PIV) insertions. The investigators hypothesize that Little NIRVANA plus a numbing cream will reduce pain and anxiety for patients undergoing PIV placement in the emergency department (ED) when compared to the cream alone. It is anticipated that using the Little NIRVANA will not increase the ED length of stay, failed PIV placement attempts, or the need for additional intervention.

Read the detailed description

This is a two-group randomized clinical trial of 65 dyads of subjects and their parent and 65 proceduralists. Children will be randomly assigned to either the Little NIRVANA intervention group or a standard of care control group. Legal guardians of children in both groups will answer questions about their child's prior history of needle procedures, current pain/anxiety, medications taken prior to ED arrival, and video game experience. Children assigned to the intervention will play the game during the PIV placement, while children in the control group will receive the standard of care. The proceduralist performing the PIV placement and the parent will answer questions after the PIV placement about their perception of the child's pain and anxiety and questions about the Little NIRVANA experience for those children who were in the intervention group. This study has one visit that is completed during their ED stay.

03

Conditions studied

  • Acute Pain
  • Procedural Anxiety
  • Pediatric ALL
  • Emergency Medicine
  • IV Access

Keywords

  • AR
  • Pain
  • Anxiety
  • Augmented Reality
  • Distraction
04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients undergoing PIV line placement (peripheral IV order placed while patient is in the ED);
  • Patients 2-8 years of age (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking (Little NIRVANA is currently only available in English and Dutch);
  • those for whom utilizing AR is deemed not feasible by the attending ED physician (e.g., critical illness)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants will receive a topical anesthetic cream and will use Little NIRVANA AR digital solution during PIV line placement

    Other: Little NIRVANA

  • No intervention
    Control

    Treatment as usual - participants will receive a topical anesthetic cream but will not use the Little NIRVANA (other distraction methods available in the ED are allowed)

Interventions

  • OtherLittle NIRVANA

    Augmented reality (AR) digital solution where children interact with the game using a magic wand

    Also known as: Augmented Reality

06

What researchers measure

Primary outcomes

  1. Proxy reported pain

    0-10 Numerical Rating Scale (NRS) (proxy reported by parent and proceduralist), 0(minimum)-10(maximum), with higher score indicating worse pain.

    Time frame: Immediately following the PIV line placement

  2. Proxy reported anxiety

    0-10 Numerical Rating Scale (NRS) (proxy reported by parent and proceduralist), 0(minimum )-10(maximum), with higher score indicating worse anxiety.

    Time frame: Immediately following the PIV line placement

Secondary outcomes

  1. Proxy reported AR experience

    0-10 Numerical Rating Scale (NRS) (proxy-reported - intervention arm only), 0(minimum )-10(maximum), with higher score meaning better outcome. Asked for fun, engagement, and satisfaction with the AR.

    Time frame: Immediately following the PIV line placement

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 27, 2025
StartActual
Nov 15, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Aug 31, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06795126
Collaborators
KU Leuven, Health Resources and Services Administration (HRSA)
Responsible party
Jonathan Chang (Emergency Medicine Physician, Nationwide Children's Hospital) — Principal investigator
First posted
Jan 27, 2025
Start date
Nov 15, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion